Kenley K. Hoover, Ph.D.

Dr. Kenley Hoover, brings more than 20 years of hands-on experience representing clients in areas including the biotechnology, pharmaceutical and chemical arts. His extensive domestic and foreign patent prosecution experience includes directing the prosecution of more than 10,000 applications and prosecuting more than 1,000 U.S. patents to issuance.

Kenley leverages his unique blend of legal, scientific, business development, and in-house acumen to provide creative, insightful, and practical solutions for meeting the strategic and business goals of his clients. His clientele ranges from emerging companies to large biopharmaceutical corporations that are established industry leaders.

A significant part of Kenley’s practice is dedicated to counseling clients on the creation and management of strategic patent portfolios and other IP assets. He also routinely advises clients on IP matters relating to all phases of drug development, from early research and development through clinical trials and commercialization.

Clients benefit from Kenley’s deep experience in creating worldwide patent prosecution strategies and evaluating portfolios directed to pharmaceuticals, antibodies and other biologics, therapeutic oligonucleotides, recombinant cell engineering, cellular therapeutics (including CAR cell and stem cell therapeutics), vaccines, gene therapy, diagnostics, biosimilars, drug formulation and delivery, medical devices, and agricultural and industrial biotechnology, among others. In addition, he regularly advises on matters relating to product-driven portfolio, lifecycle, and risk management; IP asset transfer and licensing; and patentability, freedom to operate, validity, and infringement issues.

Kenley’s in-house experience includes a decade at Human Genome Sciences Inc. (HGSI), now part of GlaxoSmithKline, where he led the IP Group and held positions including Associate General Counsel, Intellectual Property; Executive Director of Technology Assessment and Licensing; and Executive Director of Scientific Assessment. He was an integral member of HGSI’s cross-departmental teams responsible for characterizing the company’s lead targets, and for developing and shepherding drugs through clinical trials. He prosecuted HGSI’s seminal patents relating to BENLYSTA®, among others.